RVX 208: a small molecule that raises HDL

Bibliography

• Ridker PM, Genest J, Boekholdt SM et al.: HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376(9738), 333–339 (2010).
   Google Scholar
• ▪▪ In this analysis of the JUPITER trial, HDL-C is not predictive of cardiovascular risk in statin-treated patients once LDL-C levels are very low.
   Google Scholar
• Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH: The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl.), S189-S194 (2009).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al.: Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Briel M, Ferreira-Gonzalez I, You JJ et al.: Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338, B92 (2009).
   Google Scholar
• ▪ In this meta-analysis, statin-mediated increases are shown to be small and of little clinical significance.
   Google Scholar
• Brown BG, Stukovsky KH, Zhao XQ: Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17, 631–636 (2006).
   Google Scholar
• Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375(9729), 1875–1884 (2010).
   Google Scholar
• ▪ Important meta-analysis of fibrates and their outcomes.
   Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM et al.; dal-OUTCOMES Committees and Investigators: Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896–901 (2009).
   Google Scholar
• Cannon CP, Dansky HM, Davidson M et al.; DEFINE Investigators: Design of the DEFINE trial: determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib. Am. Heart J. 158(4), 513–519 (2009).
   Google Scholar
• Bailey D, Jahagirdar R, Gordon A et al.: RVX-208: a small molecule that increases Apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580–2589 (2010).
   Google Scholar
• ▪▪ First report of RVX 208 in animal and early human studies.
   Google Scholar
• Wang X, Rader DJ: Molecular regulation of macrophage reverse cholesterol transport. Curr. Opin. Cardiol. 22, 368–372 (2007).
   Google Scholar
• Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36, 211–228 (1995).
   Google Scholar
• ▪ Outlines the importance of HDL particle size in mediating reverse cholesterol transport.
   Google Scholar
• Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J Jr: Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J. Biol. Chem 279, 7384–7394 (2004).
   Google Scholar
• Hajj HH, Blain S, Boucher B, Denis M, Krimbou L, Genest J: Structural modification of plasma HDL by phospholipids promotes efficient ABCA1-mediated cholesterol release. J. Lipid Res. 46, 1457–1465 (2005).
   Google Scholar
• Hassan HH, Denis M, Lee DY et al.: Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J. Lipid Res. 48, 2428–2442 (2007).
   Google Scholar
• Hassan HH, Bailey D, Lee DY et al.: Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J. Biol. Chem. 283, 11164–11175 (2008).
   Google Scholar
• ▪ Reports the characteristics of the ATP-binding cassette A1-mediated cellular lipidation site for apoAI.
   Google Scholar
• deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51(23), 2199–2211 (2008).
   Google Scholar
• ▪ Excellent review of the pleiotropic actions of HDL and the assays to measure them.
   Google Scholar
• Sorrentino SA, Besler C, Rohrer L et al.: Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121(1), 110–122 (2010).
   Google Scholar